Eli Lilly halted a study on bimagrumab for Type 2 diabetes patients, focusing on weight loss and muscle mass preservation.

A new oral weight loss medication, orforglipron, demonstrated meaningful weight loss results in phase 3 trials, potentially ...

Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in people taking weight loss medicines.

Like many GLP-1 medications approved for diabetes, however, weight loss is a side effect of Rybelsus. “Data has shown modest ...

The 43-year-old retired tennis champ showcased her substantial weight loss in a animal-print teddy over black leggings, ...

Pfizer has been eager to develop a strong position in this area. This acquisition gives Pfizer a viable obesity drug ...

Pharmacy benefit managers are working on a proposal to voluntarily change some business practices in an effort to avoid new ...

I N recent months makers of weight-loss drugs have gone on a crash diet. In late July Novo Nordisk, the Danish firm that gave ...

The decision to stop the Phase IIb study was driven by “strategic business reasons,” according to a federal clinical trials ...

Eli Lilly has pulled the plug on a phase 2b obesity trial before enrolling a sin | Eli Lilly has pulled the plug on a phase ...

In recent weeks Novo Nordisk has secured several key label expansions for some of its products, which should contribute meaningfully to the company's results. The company's most famous weight ...

New York City doctors reveals how weight-loss drugs reduce inflammatory cytokines by decreasing fat cells, potentially preventing cancer and autoimmune diseases.